Selective estrogen receptor degrader (SERD)

This form of hormonal therapy destroys or degrades estrogen receptors to keep estrogen from binding to those receptors and encouraging breast cancer cells to grow. They include the drugs fulvestrant (Faslodex®), which is an injection for postmenopausal women with hormone receptor–positive metastatic cancer, and elacestrant (Orserdu®), which is an oral medication for postmenopausal women with estrogen receptor–positive cancer.